格隆汇1月27日丨康希诺生物(06185.HK)发布公告，根据中国企业会计准则，预计截至2025年12月31日 止年度集团实现营业收入人民币10.40亿元到人民币10.80亿元，与上年同期相比，将增加人民币1.937亿 元到人民币2.337亿元，同比增长22.88%到27.61%。预计截至2025年12月31日止年度实现归属于母公司 所有者的净利润为人民币2450万元到人民币2900万元，与上年同期相比，将实现扭亏为盈。 报告期内，集团持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫苗 曼海欣®收入保持持续增长。同时，集团深入推进降本增效，各项费用得到有效管控；产销协同进一步 优化，毛利率亦有所提升。整体盈利能力显着提升，成功于本报告期实现归属于母公司所有者的净利润 为正。 ...

每经AI快讯，康希诺1月27日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润为 2450万元~2900万元，与上年同期相比，将实现扭亏为盈。业绩变动主要原因是，主营业务影响。报告 期内，公司持续践行以创新为核心、以商业化落地为重点的发展战略，中国首款四价流脑结合疫苗曼海 欣®收入保持持续增长。同时，公司深入推进降本增效，各项费用得到有效管控；产销协同进一步优 化，毛利率亦有所提升。整体盈利能力显著提升，成功于报告期实现归属于母公司所有者的净利润为 正。非经常性损益的影响。报告期内，随着公司研发项目的快速推进及国际合作的开展，公司获得了更 多政府专项补助及国际专项资金的支持，故于报告期产生较大金额的非经常性收益。 （记者 王瀚黎） 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 ...

（文章来源：每日经济新闻） 每经AI快讯，康希诺(688185)1月27日公告，预计2025年实现营业收入10.4亿元到10.8亿元，同比增长 22.88%到27.61%。归属于母公司所有者的净利润预计为2450万元到2900万元，同比扭亏为盈。报告期 内，公司中国首款四价流脑结合疫苗曼海欣®收入保持持续增长。同时，公司深入推进降本增效，各项 费用得到有效管控；产销协同进一步优化，毛利率亦有所提升。 ...

格隆汇1月27日｜康希诺公告，预计2025年年度实现归属于母公司所有者的净利润为2450万元到2900万 元，与上年同期相比，将实现扭亏为盈。报告期内，公司持续践行以创新为核心、以商业化落地为重点 的发展战略，中国首款四价流脑结合疫苗曼海欣收入保持持续增长。 ...

本 公 告 由 康 希 諾 生 物 股 份 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱 為「本集團」）根 據 香 港 聯 合 交 易 所 有 限 公 司 證 券 上 市 規 則（「上市規則」）第13.09條及香港法例第 571章證券及期貨條例第XIVA部內幕消息條文發佈。 一、本期業績預告情況 康希諾生物股份公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6185） 內幕消息 2025年年度業績預告 （一）業績預告期間 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部 或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責任。 CanSino Biologics Inc. – 1 – 1、 根 據 中 國 企 業 會 計 準 則，預 計 截 至2025年12月31日止年度本集團 實現營業收入人民幣1,040.0百萬元到人民幣1,080.0百萬元，與上年 同 期 相 比，將 增 加 人 民 幣193.7百萬元到人民幣233.7百 萬 元，同 比 增 長22.88%到27.61%。 2、 ...

中信证券投资有限公司（参与跟投的保荐机构相关公司）获配股票数量为49.60万股，占本次发行总股 数的2.00%，跟投金额为1.04亿元。 (责任编辑：马欣) 康希诺首次公开发行股票募集资金总额为52.01亿元，扣除发行费用后，募集资金净额为49.79亿元。康 希诺最终募集资金净额较原计划多39.79亿元。康希诺于2020年8月6日发布的招股说明书显示，该公司 计划募集资金10亿元，分别用于"生产基地二期建设""在研疫苗开发""疫苗追溯、冷链物流体系及信息 系统建设""补充流动资金"。 康希诺首次公开发行股票的发行费用为2.21亿元，其中保荐及承销费用2.05亿元。 中国经济网北京1月27日讯 康希诺(688185.SH)今日股价下跌，截至收盘，该股报74.33元，跌幅3.73%。 该股目前处于破发状态。 康希诺于2020年8月13日在上交所科创板上市，发行数量为2480万股，发行价格209.71元/股，保荐机构 （主承销商）为中信证券，保荐代表人为焦延延、马可；联席主承销商为中金公司，副主承销商为渤海 证券。 ...

证券代码：688185 证券简称：康希诺 公告编号：2026-002 康希诺生物股份公司 2025 年年度业绩预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 1、经康希诺生物股份公司（以下简称"公司"）财务部门初步测算，预计 2025 年 年 度 （ 以 下 简 称 " 报 告 期 " ） 实 现 营 业 收 入 104,000.00 万 元 到 108,000.00 万元，与上年同期相比，将增加 19,366.19 万元到 23,366.19 万元，同 比增长 22.88%到 27.61%。 2、预计 2025 年年度实现归属于母公司所有者的净利润为 2,450.00 万元到 2,900.00 万元，与上年同期相比，将实现扭亏为盈。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况 公司 2024 年年度实现营业收入为 84,633.81 万元，利润总额为-38,120. ...

Group 1 - The recent outbreak of Nipah virus in West Bengal, India, has led to 5 confirmed cases, with one patient in critical condition, prompting enhanced preventive measures in neighboring countries like Thailand and Nepal [1] - Nearly 100 individuals have been placed under home quarantine, and infected patients are receiving treatment in hospitals in Kolkata and surrounding areas [1] - The Nipah virus is a zoonotic virus that can be transmitted from infected animals to humans, with symptoms including acute respiratory infections and potentially fatal encephalitis, and there is currently no approved vaccine or specific treatment available [1][4] Group 2 - The stock prices of vaccine and in vitro diagnostic (IVD) sectors surged following the news, with companies like Hualan Biological (301207) and Jindike experiencing significant gains, reaching their daily limit [1][2] - The vaccine index rose by 6.60%, with notable increases in stock prices for companies such as Hualan Vaccine (20.00%), Jindike (19.98%), and Zhifei Biological (14.87%) [2] - The market response indicates a heightened interest in companies involved in vaccine development and diagnostic testing related to the Nipah virus [1][8] Group 3 - Nipah virus is classified as a high-pathogenicity pathogen with a mortality rate ranging from 40% to 75%, and it has been recognized as a significant public health threat for over 25 years [3][5] - The virus's natural reservoir is fruit bats, which can transmit the virus through contaminated food or environments, and outbreaks have primarily occurred in South and Southeast Asia [3][5] - Current detection methods include antibody and nucleic acid testing, with companies like Zhijiang Biological and Daan Gene developing specific test kits for Nipah virus detection [6][7] Group 4 - Companies are actively developing testing solutions, with Zhijiang Biological's Nipah virus PCR test kit achieving high sensitivity and rapid results, and Daan Gene's kit also showing promising detection capabilities [7] - Research into vaccines for Nipah virus is ongoing, with some candidates entering clinical trials, and monoclonal antibodies showing potential in compassionate use [8] - The stock prices of companies involved in vaccine development, such as Watson Bio, Zhifei Bio, and Hualan Vaccine, have seen increases, reflecting investor optimism regarding potential solutions to the Nipah virus threat [8]

Core Viewpoint - The recent outbreak of Nipah virus in West Bengal, India, has raised concerns, leading to increased preventive measures in neighboring countries and a significant rise in stock prices of vaccine and IVD companies in the A-share market [1][12]. Group 1: Nipah Virus Overview - Nipah virus (NiV) is a zoonotic RNA virus with a high mortality rate, classified as a biosafety level 4 pathogen by WHO, with a fatality rate ranging from 40% to 75% [6][8]. - The natural reservoir for Nipah virus is fruit bats, which can transmit the virus to humans through contaminated food or environments [6][8]. - Recent data indicates that India has experienced a resurgence of Nipah virus cases, particularly in Kerala and now West Bengal, with localized outbreaks showing high fatality rates [7][8]. Group 2: Market Impact - Following the news of Nipah virus cases, the A-share vaccine and IVD sectors saw a collective surge, with companies like Hualan Biological and Jindike hitting the daily limit up [1][12]. - Specific stock performances included Hualan Biological at 23.34 with a 20% increase, Jindike at 25.28 with a 19.98% increase, and others like Zhifei Biological and CanSino also showing significant gains [2][3]. Group 3: Detection and Response - Early detection of Nipah virus is crucial, with the incubation period ranging from 3 to 14 days, and initial symptoms resembling flu, which can lead to misdiagnosis [10][12]. - Various detection methods are in use, including antibody and nucleic acid tests, with companies like Zhijiang Biological and Daan Gene developing specific test kits for Nipah virus [10][11]. - The new revised "Law on Frontier Health and Quarantine" in China includes Nipah virus in its detection protocols, highlighting the importance of monitoring and response [10]. Group 4: Vaccine Development - Although there is currently no approved treatment for Nipah virus, research is ongoing, with vaccines entering clinical trials and monoclonal antibodies showing potential in compassionate use [12]. - Companies involved in vaccine development, such as Watson Bio, Zhifei Biological, and Hualan Biological, have seen stock price increases, reflecting investor optimism regarding potential future products [12].

Group 1: Nipah Virus Outbreak in India - The Nipah virus infection cases have been reported in West Bengal, India, with 5 confirmed cases, including healthcare workers, and nearly 100 individuals under home quarantine [1] - One patient is in critical condition, and the infected individuals are receiving treatment in Kolkata and surrounding hospitals [1] Group 2: Market Reaction - Following the news, the A-share market saw significant movements in sectors such as flu vaccines, diagnostic reagents, and chemical pharmaceuticals, with several stocks hitting the daily limit [2] - Notable stock performances include Hualan Vaccine (20% increase), Jindike (19.98% increase), and Zhifei Biological (14.87% increase) [2][3] Group 3: Vaccine and Diagnostic Kit Development - Companies in the IVD medical device sector, including Maike Biological and Cap Biological, launched Nipah virus test kits, with prices ranging from 100 to 2899 yuan [5][6] - The development of Nipah virus vaccines is considered technically feasible, but companies face challenges due to low vaccination willingness and market conditions [5] Group 4: Regulatory and Preventive Measures - China has strengthened its legal framework for controlling infectious diseases, including the Nipah virus, with new regulations effective from January 1, 2025 [7] - Enhanced health monitoring measures have been implemented at airports in Thailand for travelers from India due to the outbreak [7]